Incredible results for Q4 y/eHuge yoy reduction in debt. Normalized credit metrics. Record US ebitda. Rates exceeding inflationary costs. Fully booked Q1 with stronger than expected visibility into Q2. Rapidly tightening market. Calfrac is becoming distressed. Doubt we stay below $4 for much longer... let alone $2. Great work by STEP!